Viridian Therapeutics, Inc. (VRDN) Tops Q4 EPS by 64c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q4 EPS of ($0.34), $0.64 better than the analyst estimate of ($0.98). Revenue for the quarter came in at $70.57 million versus the consensus estimate of $18.38 million.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Citi raises Atlassian price target to $225, maintains Buy rating
• Goldman Sachs Upgrades Drax Group Plc. (DRX:LN) (DRXGY) to Buy
• UBS Downgrades Zhaojin Mining Industry Co Ltd (1818:HK) to Neutral